Article | September 16, 2020

The Data Quality & Master Files Challenge For FDA Submissions

Source: Cytiva
FDA Approved

From its beginnings in 2016, Celularity Inc.’s Dr. Robert Hariri knew his company would face a particularly acute challenge with the FDA. The company’s therapeutic approach—the development of medicine from allogeneic placental-derived cells—is entirely dependent on its ability to do something that had never been done before: accomplish the at-scale harvest and preservation of healthy, postpartum fetal stem cells from maternity wards far-and-wide.

That’s not something the FDA would take lightly, and Dr. Hariri knew it. But this wasn’t his first rodeo. He knew that to pass muster with the Agency, Celularity would have to demonstrate a diligent commitment to data quality, master files, and reporting.

Dr. Hariri shared some of his wisdom on the topic during a recent episode of The Business Of Biotech podcast (produced by BioProcess Online in partnership with Cytiva).

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: